Profile: Novavax Inc (NVAX.O)
24 Feb 2017
Novavax, Inc. (Novavax), incorporated on June 18, 1987, is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS). The Company through its subsidiary, Novavax AB, is also developing a technology for the production of immune stimulating saponin-based adjuvants.
The Company is developing respiratory syncytial virus fusion (F) protein nanoparticle vaccine candidate (RSV F vaccine candidate) for approximately three target populations: the older adults (approximately 60 years of age and above), infants through maternal immunization and children six months to five years of age (pediatrics). The Company through its RSV Older Adults Program is developing RSV F vaccine candidate, which is in Phase II of clinical trial. The Company through its RSV Infants via Maternal Immunization Program is developing RSV F vaccine candidate, which is in Phase II of clinical trial. This clinical trial evaluated the safety and immunogenicity of its RSV F Vaccine in pregnant women in their third trimester and assessed the transplacental transfer of maternal antibodies induced by the vaccine. The trial also examined the impact of maternal immunization on infant safety during the first year of life and RSV-specific antibody levels through the infants' first six months of life. Its RSV Pediatric Program is developing RSV F Vaccine candidate, which is in Phase I of clinical trial. This clinical trial evaluated the safety and immunogenicity of its RSV F Vaccine, with one or two doses, with or without aluminum phosphate adjuvant.
The Company's vaccine candidates for Influenza include Seasonal Quadrivalent Influenza virus-like particle (VLP) Vaccine and Pandemic H7N9 Influenza Vaccine. Its quadrivalent seasonal influenza VLP vaccine is in Phase II of clinical trial. It is focused on developing and delivering immunogenicity data on over two pandemic vaccine candidates, H5N1 and H7N9. The Company is also developing vaccine candidates for Ebola Virus. Ebola EBOV glycoprotein vaccine candidate (Ebola GP Vaccine) is in Phase I stage of clinical development. Its Ebola GP Vaccine was developed using the Makona EBOV strain. The Company has a joint venture with Cadila Pharmaceuticals Limited (Cadila) and CPL Biologics Private Limited (CPLB). The Company through Cadila and CPLB is focused on developing and manufacturing vaccine candidates. Seasonal VLP influenza vaccine candidate is in Phase III of clinical development and rabies vaccine is in Phase I/II of clinical development.
The company competes with Merck & Co., Inc., GlaxoSmithKline plc, CSL Ltd, Sanofi Pasteur, SA, Pfizer Inc. and AstraZeneca PLC.
20 Firstfield Rd
GAITHERSBURG MD 20878-1760